Pluristem looks to be in for a good day after receiving approval to manufacture its PLacental expanded cell products in its new commercial-scale cell manufacturing facility from the U.S. Pluristem Therapeutics Inc. (NASDAQ:PSTI) stock opened at $4.30 in last session, and closed at $4.23, while the day range of Pluristem Therapeutics Inc. (NASDAQ:PSTI) stock is $4.12 – $4.36. The stock showed a positive weekly performance of 2.42%.
StemCells, Inc. (NASADQ:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced on 5 march that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells Inc. (NASDAQ:STEM) stock opened at $1.59 in last session, and closed at $1.57 by gaining 1.29%. The 52 week range of $1.16 – $1.95. Company’s market capitalization is $65.00 million.
Synageva BioPharma Corp. (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced the pricing of its previously announced underwritten public offering of common stock consisting of 2.0 million shares at $105.75 per share Synageva BioPharma Corp (NASDAQ:GEVA) stock decreased -7.05% and finished the last session at $98.29. The EPS of the stock remained -3.00. Company’s market capitalization is $2.70 billion.
Lpath, Inc. (NASDAQ:LPTN), the industry leader in bioactive lipid-targeted therapeutics, has brought scientists one step closer to finding a potential treatment for traumatic brain injury (TBI) with a recent publication showing that Lpathomab™, a therapeutic antibody, reverses much of the damage caused by trauma to the nervous system. Lpath, Inc. (NASDAQ:LPTN) stock opened the session at $4.50, and closed the session at $4.82. The 52 week range of the Lpath, Inc. (NASDAQ:LPTN) stock remained $3.87 – $6.70 and the day range was $4.50 – $5.00.
Leave a Reply